Clinical Trial Update: 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks [Phase 2]

View source ↗

Summary

Phase 2 trial comparing 68Ga-RM2 to 68Ga-PSMA-617 PET/CT for imaging prostate cancer across different metastatic risk categories has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-PSMA-617 PET/CT (PSMA-617)
• 68Ga-RM2

Snippet

Sponsor: University Hospital, Bordeaux | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED